How to buy Ardelyx stock | $1.08

Ardelyx Inc is a biotechnology business based in the US. Ardelyx shares (ARDX) are listed on the NASDAQ and all prices are listed in US Dollars. Ardelyx employs 129 staff and has a trailing 12-month revenue of around 0.00.

Ardelyx stock price (NASDAQ: ARDX)

Use our graph to track the performance of ARDX stocks over time.

Ardelyx shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$1.08
52-week range	$1.05 - $9.23
50-day moving average	$1.32
200-day moving average	$4.73
Wall St. target price	$6.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.33

Buy Ardelyx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Ardelyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ardelyx price performance over time

Historical closes compared with the close of $1.08 from 2021-10-15

1 week (2021-10-08)	-13.60%
1 month (2021-09-17)	-17.56%
3 months (2021-07-17)	-86.58%
6 months (2021-04-16)	-87.57%

1 year (2020-10-16)	-81.12%
2 years (2019-10-17)	-76.67%
3 years (2018-10-17)	3.93
5 years (2016-10-17)	12.65

Ardelyx financials

Revenue TTM	$12.4 million
Gross profit TTM	$-57,627,000
Return on assets TTM	-36%
Return on equity TTM	-94.98%
Profit margin	0%
Book value	$1.14
Market capitalisation	$111.4 million

TTM: trailing 12 months

Shorting Ardelyx shares

There are currently 6.6 million Ardelyx shares held short by investors – that's known as Ardelyx's "short interest". This figure is 16% down from 7.9 million last month.

There are a few different ways that this level of interest in shorting Ardelyx shares can be evaluated.

Ardelyx's "short interest ratio" (SIR)

Ardelyx's "short interest ratio" (SIR) is the quantity of Ardelyx shares currently shorted divided by the average quantity of Ardelyx shares traded daily (recently around 3.1 million). Ardelyx's SIR currently stands at 2.14. In other words for every 100,000 Ardelyx shares traded daily on the market, roughly 2140 shares are currently held short.

However Ardelyx's short interest can also be evaluated against the total number of Ardelyx shares, or, against the total number of tradable Ardelyx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ardelyx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ardelyx shares in existence, roughly 60 shares are currently held short) or 0.087% of the tradable shares (for every 100,000 tradable Ardelyx shares, roughly 87 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ardelyx.

Find out more about how you can short Ardelyx stock.

Ardelyx share dividends

We're not expecting Ardelyx to pay a dividend over the next 12 months.

Ardelyx share price volatility

Over the last 12 months, Ardelyx's shares have ranged in value from as little as $1.05 up to $9.23. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ardelyx's is 1.8196. This would suggest that Ardelyx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ardelyx overview

Ardelyx, Inc. , a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.

Frequently asked questions

What percentage of Ardelyx is owned by insiders or institutions?
Currently 1.569% of Ardelyx shares are held by insiders and 84.626% by institutions. How many people work for Ardelyx?
Latest data suggests 129 work at Ardelyx. When does the fiscal year end for Ardelyx?
Ardelyx's fiscal year ends in December. Where is Ardelyx based?
Ardelyx's address is: 34175 Ardenwood Boulevard, Fremont, CA, United States, 94555 What is Ardelyx's ISIN number?
Ardelyx's international securities identification number is: US0396971071 What is Ardelyx's CUSIP number?
Ardelyx's Committee on Uniform Securities Identification Procedures number is: 039697107